R

RTW Investments

Lifecycle-focused life sciences investor

Digital Media Manager

Full-Time
$140k - $170k/yr+ Discretionary incentive compensation
Senior
Bachelor's
New York, NY, USA
In Person
Growth & MarketingMarketing Generalist & Management

About the job

Requirements
  • A bachelor's degree.
  • At least 5 years of experience in digital media, social media strategy, or content marketing.
  • Expertise in platform algorithms, content formats, and engagement best practices across LinkedIn, X, and Instagram, with the ability to identify trends and adapt strategy independently.
  • Fluency in digital media analytics, including defining key performance indicators, building performance dashboards, and translating data into strategic recommendations across social, paid, email, and web channels.
  • Experience with Google Analytics 4 for web analytics, content, user experience, and search engine optimization recommendations.
  • Familiarity with search engine optimization and generative engine optimization best practices.
  • Website content management experience, including end-to-end ownership and vendor relationship management.
  • Experience coordinating video production or podcast pipelines with external producers.
  • Graphic design fluency in Canva or an equivalent tool.
  • Strong written communication skills for professional, scientific, and investor audiences.
  • Experience managing a customer relationship management or email marketing platform end to end, including audience segmentation and compliance with CAN-SPAM and GDPR.
  • Ability to work from RTW's New York City office.
Responsibilities
  • Drive RTW's social media strategy across LinkedIn, X (Twitter), and Instagram, applying the distinct role of each platform.
  • Stay current with algorithm changes and format-specific best practices, make operational platform decisions within brand guardrails, and escalate executive positioning, portfolio company, investment theme, or compliance-sensitive decisions to the Director of Communications.
  • Develop and manage a monthly social content calendar and maintain consistent publishing across RTW's firm account and selected executive channels.
  • Define, monitor, and report on digital media key performance indicators, including reach, engagement rate, click-through rate, cost per thousand impressions, conversion, and earned share of voice.
  • Plan, execute, and optimize paid social campaigns across LinkedIn and X, including A/B testing of creative formats, copy, and audience segments.
  • Own campaign goals and key performance indicators end to end, manage budgets, and deliver regular reports with actionable optimization recommendations.
  • Own the RTW website, including content management, design updates, vendor relationship management, user experience improvements, and Google Analytics 4-driven content and conversion recommendations.
  • Own RTW's search engine optimization and generative engine optimization strategy for traditional search and AI-powered discovery tools.
  • Launch and manage RTW's content subscription and marketing platform, including audience segmentation, subscriber journey design, and email marketing campaigns compliant with CAN-SPAM, GDPR, and Regulation Fair Disclosure.
  • Track and report email performance metrics, including open rates, click-through rate, and list growth, and recommend ongoing optimizations.
  • Write and edit social media copy, campaign content, email subject lines, and newsletter content while maintaining RTW's voice and compliance standards.
  • Create or direct digital graphic assets in Canva for social and digital use.
  • Coordinate the full RTW podcast production pipeline with the Director of Communications and external vendors, including content briefs, guest recruitment, review cycles, publication timelines, and social amplification.
  • Route content through RTW's communications review workflow and ensure material follows the appropriate executive and compliance review sequence with clear priority designation before publication.
Desired Qualifications
  • Experience in healthcare, biotechnology, financial services, or business-to-business professional services.
  • Experience with HubSpot or an equivalent customer relationship management or email marketing platform.
  • Experience in digital health, biotechnology, life sciences, or financial and investment communications.
  • Familiarity with compliance-sensitive content environments, including the Securities and Exchange Commission, Financial Industry Regulatory Authority, Regulation Fair Disclosure, or pharmaceutical and healthcare regulatory frameworks.

About the company

RTW Investments, LP focuses on life sciences across the full investment lifecycle, moving assets from early research through commercialization. Its activities include creating companies from academic work, venture and crossover investing, and public-market positions, with discretionary advisory services for its Flagship and Innovation funds. The firm differentiates itself by combining early-stage company creation with later-stage and public-market investments, enabling long-term partnerships and deeper involvement, with offices in New York, London, and Shanghai. Its goal is to bring transformative biopharmaceutical and medical-technology assets to market, improving patient outcomes while delivering returns for its funds.

Company Size

N/A

Company Stage

N/A

Total Funding

$14.1B

Headquarters

New York City, New York

Founded

2010

Get referred to RTW Investments

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • BioMarin bought Alesta in August 2026, validating RTW’s portfolio-construction playbook.
  • RTW backed Candel’s $100 million royalty financing in February 2026.
  • RTW announced seven and eight M&A outcomes since summer 2025, per April 2026.

What critics are saying

  • RTW Bio held 70.9% public equities and 24.0% private investments on 2025-12-31.
  • Top ten 13F positions represented 47.7% of reported value as of 2026-08.
  • Clinical failures at Madrigal, Insmed, Protagonist, or PTC erase marks within quarters.

What makes RTW Investments unique

  • RTW spans company creation to public markets, unlike single-stage biotech investors.
  • Roderick Wong’s team combines MD, MBA, and 2026 cross-border scientific underwriting.
  • RTW keeps monetizing through 2026 M&A, royalty deals, and IPOs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

Company News

Associated Press
Sep 9th, 2026
Encoded Therapeutics raises $275M Series F to advance Dravet syndrome gene therapy into pivotal trials

Encoded Therapeutics has closed a $275 million Series F financing round co-led by GV and another healthcare fund. The clinical-stage biotechnology company develops precision genetic medicines for severe neurological disorders. The proceeds will fund a pivotal study of ETX101 in infants and young children with SCN1A+ Dravet syndrome, plus an expansion study for children and adolescents up to 18 years. The funding will also support commercial-scale GMP manufacturing and pipeline advancement, including ETX301 towards a 2027 Investigational New Drug submission for post-amputation neuroma pain. Participating investors include ARCH Venture Partners, Braidwell LP, Farallon Capital Management, Illumina Ventures, Invus, Janus Henderson Investors, Matrix Capital Management, Nolan Capital, RTW Investments, SoftBank Vision Fund 2, and Venrock.

PR Newswire
Aug 10th, 2026
Avere Therapeutics raises $500M to advance once-weekly oral IL-23 therapy AVR-001

Avere Therapeutics announced a $500 million private placement to advance AVR-001, its once-weekly oral IL-23 receptor antagonist for inflammatory diseases. Leading healthcare investors including Venrock Healthcare Capital Partners, General Atlantic, Blackstone Multi-Asset Investing, and Wellington Management participated in the funding round. Combined with a previously announced $320 million concurrent private investment, the proceeds will fully fund Avere's operations through 2029. The financing will close alongside Avere's merger with NextCure, expected in the second half of 2026. Upon completion, the combined company will operate as Avere Therapeutics and trade on Nasdaq under ticker symbol "AVRX." Avere is initially developing AVR-001 for psoriasis, with potential expansion into ulcerative colitis, Crohn's disease, and psoriatic arthritis.

Central Charts
Aug 6th, 2026
Tarsus Pharmaceuticals raises $125M in oversubscribed PIPE financing to fund Alkeus acquisition

Tarsus Pharmaceuticals has secured $125 million through an oversubscribed private placement equity financing. The transaction includes participation from investors in Alkeus Pharmaceuticals, which Tarsus announced it would acquire earlier the same day. Notable investors include TCGX, Bain Capital Life Sciences, Wellington Management, ADAR1 Capital Management, Sirenia Capital Management LP, RTW Investments, and Vestal Point Capital. The company is selling 2,098,519 shares of common stock at $56 per share and pre-funded warrants to purchase 133,625 additional shares. The financing is expected to close on 7 August 2026. Tarsus intends to use the proceeds to fund clinical development, commercial activities, and general corporate purposes. Barclays is serving as lead placement agent, with BofA Securities and William Blair as co-placement agents.

StreetInsider
Jul 22nd, 2026
Mentari Therapeutics raises $200M to advance migraine prevention pipeline through Phase 2a readouts

Mentari Therapeutics, a biotechnology company developing migraine prevention therapies, has secured $200 million in a private placement from leading healthcare investors. The funding will support the development of Mentari's pipeline of targeted biologics for migraine treatment. Investors include Fairmount, ADAR1 Capital Management, Venrock Healthcare Capital Partners, Sirenia Capital Management, Janus Henderson Investors, Blackstone Multi-Asset Investing, RTW Investments, Deep Track Capital, Vivo Capital, Commodore Capital, BB Biotech, and others. The financing extends Mentari's cash runway into 2029 and through Phase 2a readouts on two PACAP-targeted lead programmes, including MT-002. The private placement will close immediately before Mentari's merger with InMed Pharmaceuticals and concurrently with a previously announced $290 million private placement. Jefferies, TD Cowen, Stifel, and Guggenheim Securities are acting as placement agents.

PR Newswire
Jul 22nd, 2026
Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline

/PRNewswire/ -- Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, today announced a...